SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): May 20, 2005
CEL-SCI CORPORATION
--------------------------
(Exact name of Registrant as specified in its charter)
Colorado 0-11503 84-0916344
-------------------------------------------------------------------------------
(State or other jurisdiction (Commission File No.) (IRS Employer
of incorporation) Identification No.)
8229 Boone Boulevard, Suite 802
Vienna, Virginia 22182
----------------------------------------
(Address of principal executive offices, including Zip Code)
Registrant's telephone number, including area code: (703) 506-9460
--------------
N/A
---------------------------------------------
(Former name or former address if changed since last report)
Item 8.01 Other Events
On May 20, 2005, the Company issued a press release regarding the results
of a Phase II clinical trial using Multikine to treat head and neck cancer. A
copy of this press release is attached as an exhibit.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: May 24, 2005
CEL-SCI CORPORATION
By: /s/ Geert R. Kersten
-----------------------------------------
Geert R. Kersten, Chief Executive Officer